Related Experiment Video
Updated: Feb 7, 2026

Label-Free Identification of Lymphocyte Subtypes Using Three-Dimensional Quantitative Phase Imaging and Machine Learning
Published on: November 19, 2018
Identification of molecular features necessary for selective inhibition of B cell lymphoma proteins using machine
Ahmad Mani-Varnosfaderani1,2, Marzieh Sadat Neiband3, Ali Benvidi3
1Department of Chemistry, Tarbiat Modares University, Tehran, Iran. a.mani@modares.ac.ir.
Abstract:
Selective inhibition of Bcl-2 and Bcl-xL proteins due to their dual inhibition toxicity plays an important role in treatment of cancer and chemotherapy effectiveness; therefore, in the last decade, discovery of selective inhibitors for Bcl-2 and Bcl-xL proteins has become a significant and important research topic. The present contribution paves the way for characterization of molecular features which induce selectivity for inhibition of Bcl-2 and Bcl-xL. In this line, a total of 1534 molecules related to inhibition of Bcl-2 and Bcl-xL proteins were collected from Binding Database. A diverse set of molecular descriptors was calculated for each molecule, and the best subset of descriptors were selected using variable importance in projection (VIP) approach. The molecules were classified according to their therapeutic targets (Bcl-2/Bcl-xL) and activities. Partial least square-discriminate analysis (PLS-DA) and supervised Kohonen network (SKN) models were utilized to relate the molecular structures of chemicals to their activities and selectivities. According to the VIP-selected descriptors physicochemical properties, such as polarity number, number of branches, size and cyclicity of the molecule, flexibility, functional counts and constitutional descriptors, all affect the activities of Bcl-2 and Bcl-xL inhibitors. The performances of PLS-DA and SKN methods were evaluated based on statistical parameters derived from the confusion matrices. The models were validated using tenfold cross-validation and an external test set. The best statistical results were obtained by implementing the SKN model. The classification rates range from 93.5 to 79.1% for the training and validation procedure for the optimized SKN models. The high values of the obtained classification rates demonstrate that the information provided in this work would be useful to design new drugs with selective inhibitory activities toward Bcl-2 or Bcl-xL proteins for more effective treatment of cancer.
Insights
Researchers identified key molecular features for selective Bcl-2 and Bcl-xL protein inhibition, crucial for cancer treatment. This study aids in designing more effective cancer drugs by understanding structure-activity relationships for these protein inhibitors.
Area of Science:
- Medicinal Chemistry
- Computational Biology
- Drug Discovery
Background:
- Selective inhibition of Bcl-2 and Bcl-xL proteins is vital for cancer treatment and chemotherapy efficacy.
- Developing selective inhibitors for these proteins is a significant research focus due to dual inhibition toxicity.
- Understanding the molecular features driving selectivity is key to advancing cancer therapeutics.
Purpose of the Study:
- To characterize the molecular features that induce selectivity for Bcl-2 and Bcl-xL protein inhibition.
- To build predictive models relating molecular structure to inhibitory activity and selectivity.
- To guide the design of novel, selective inhibitors for Bcl-2 or Bcl-xL.
Main Methods:
- Collected 1534 molecules targeting Bcl-2 and Bcl-xL from the Binding Database.
- Calculated molecular descriptors and selected the most relevant using the Variable Importance in Projection (VIP) approach.
- Employed Partial Least Square-Discriminant Analysis (PLS-DA) and Supervised Kohonen Network (SKN) models for structure-activity relationship analysis.
Main Results:
- Physicochemical properties like polarity, branching, size, cyclicity, flexibility, and functional/constitutional descriptors influence inhibitor activity.
- The Supervised Kohonen Network (SKN) model demonstrated superior performance compared to PLS-DA.
- Optimized SKN models achieved high classification rates, ranging from 93.5% (training) to 79.1% (validation).
Conclusions:
- The identified molecular features are crucial for designing selective Bcl-2 or Bcl-xL inhibitors.
- The predictive models provide valuable insights for developing next-generation cancer therapeutics.
- This research facilitates the creation of more effective drugs targeting specific apoptotic regulators in cancer therapy.
Related Concept Videos
Molecular Chaperones and Protein Folding
The...
Molecular Chaperones and Protein Folding
Feedback Inhibition
Antibiotic Selection
Machines
A free-body diagram of the...
Frequency-dependent Selection

